Objective
Therapeutic vaccines targeting B cell non-Hodgkin lymphoma (NHL) idiotype (Id) represent a promising immunotherapeutic approach for a more effective control of these malignancies. A broad use of Id-based vaccination, however, is hampered by the complexity and costs due to the individualized production of these vaccines. Recent evidence suggests that these limitations may be overcome. In fact, distinct sets of stereotyped immunoglobulins have been identified in various B-NHL, suggesting that a much higher frequency of shared Id exists among patients than appreciated previously. We found that the VK3-20 protein, frequently expressed by HCV-related B-NHL, induces specific T cell responses that cross-react against related VK proteins commonly used by different B cell lymphoproliferations. These findings provide the rationale to develop recombinant vaccines using Id shared by different B cell malignancies. Through the complementary and synergistic work of academic partners and three SMEs, we plan to develop and produce optimized recombinant Id vaccines for subset-specific immunotherapy. A database of VH and VL sequences expressed by low-grade B-NHL and chronic lymphocytic leukemias will be established and analyzed to identify subgroups of tumours expressing molecularly correlated Id proteins. Selected Id proteins will be characterized for their immunogenicity and, particularly, for the ability to induce 'cross-reactive¿ immune responses against related Id proteins. B and T cell epitopes will be identified using innovative approaches (pentamer libraries, MATRIX-SCAN) and dedicated assays for immunomonitoring will be developed. Moreover, optimized versions of selected Id vaccines will be produced using new strategies (Gly-Ala repeat insertion, peptide sequence optimization) and validated in animal models. New adjuvants and delivery systems for improved Id vaccine formulations and administration will be also evaluated and validated. The most promising Id proteins will be...
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences health sciences infectious diseases RNA viruses HIV
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- medical and health sciences clinical medicine hematology
- medical and health sciences basic medicine immunology immunotherapy
- medical and health sciences clinical medicine oncology leukemia
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP6-2005-LIFESCIHEALTH-7
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
AVIANO PN
Italy
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.